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Abstract
Systemic lupus erythematosus (SLE) is a genetically complex disease with heterogeneous clinical manifestations. A
polymorphism in the STAT4 gene has recently been established as a risk factor for SLE, but the relationship with specific SLE
subphenotypes has not been studied. We studied 137 SNPs in the STAT4 region genotyped in 4 independent SLE case series
(total n=1398) and 2560 healthy controls, along with clinical data for the cases. Using conditional testing, we confirmed the
most significant STAT4 haplotype for SLE risk. We then studied a SNP marking this haplotype for association with specific
SLE subphenotypes, including autoantibody production, nephritis, arthritis, mucocutaneous manifestations, and age at
diagnosis. To prevent possible type-I errors from population stratification, we reanalyzed the data using a subset of subjects
determined to be most homogeneous based on principal components analysis of genome-wide data. We confirmed that
four SNPs in very high LD (r
2=0.94 to 0.99) were most strongly associated with SLE, and there was no compelling evidence
for additional SLE risk loci in the STAT4 region. SNP rs7574865 marking this haplotype had a minor allele frequency
(MAF)=31.1% in SLE cases compared with 22.5% in controls (OR=1.56, p=10
216). This SNP was more strongly associated
with SLE characterized by double-stranded DNA autoantibodies (MAF=35.1%, OR=1.86, p,10
219), nephritis (MAF=34.3%,
OR=1.80, p,10
211), and age at diagnosis,30 years (MAF=33.8%, OR=1.77, p,10
213). An association with severe
nephritis was even more striking (MAF=39.2%, OR=2.35, p,10
24 in the homogeneous subset of subjects). In contrast,
STAT4 was less strongly associated with oral ulcers, a manifestation associated with milder disease. We conclude that this
common polymorphism of STAT4 contributes to the phenotypic heterogeneity of SLE, predisposing specifically to more
severe disease.
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Introduction
Systemic lupus erythematosus (SLE) (OMIM 152700) is a
disabling and chronic autoimmune disease with remarkable
heterogeneity. The eleven classification criteria for SLE estab-
lished by the American College of Rheumatology [1] – any four of
which can confirm classification as SLE – include arthritis, renal
disease, mucocutaneous manifestations, photosensitivity, neuro-
logical disorders, production of a variety of autoantibodies, and
hematological disorders. Many of these characteristics are
correlated, and may indicate different underlying disease mech-
anisms. SLE also has an established but complex genetic
component [2]. Understanding the relationships between SLE
risk genes and subtypes of the disease may help to elucidate disease
mechanisms and pathways.
Recently, a polymorphism of the STAT4 gene on chromosome
2q has been strongly implicated in the risk for both SLE and
rheumatoid arthritis [3]. We investigated whether variation in
PLoS Genetics | www.plosgenetics.org 1 May 2008 | Volume 4 | Issue 5 | e1000084STAT4 contributes to the heterogeneity of SLE. Using 4
independent SLE case series, a large set of healthy controls, and
two independent sets of genotypes for the STAT4 region on these
subjects, we have found strong evidence that this is the case. In
particular, we have found that the STAT4 susceptibility polymor-
phism is associated with more severe disease manifestations,
including nephritis and early disease onset. It is also strongly
associated with SLE characterized by double-stranded DNA
autoantibody production.
Methods
Subjects
SLE cases were obtained from four sources. Patients from the
University of California, San Francisco (UCSF) were participants
in the UCSF Lupus Genetics Project and were recruited from
UCSF Arthritis Clinics and private rheumatology practices in
northern California, as well as by nationwide outreach [4]. SLE
patients contributed by the Autoimmune Biomarkers Collabora-
tive Network (ABCoN) [5] were recruited from the Hopkins Lupus
cohort [6]. A third case series was part of the Multiple
Autoimmune Disease Genetics Consortium (MADGC) collection
[7]. Finally, a fourth set of cases recruited from the Pittsburgh
Lupus Registry were obtained from the University of Pittsburgh
[8]. Only subjects of self-described European descent were
retained. Unrelated controls of European ancestry were from the
New York Health Project (NYHP) [9] (http://www.amdec.org/
amdec_initiatives/nycp.html). The study populations are a super-
set of those recently used to establish a link between SLE and
STAT4 [3], with the addition of the University of Pittsburgh cases
and more than doubling the number of NYHP controls (see
Table 1). The Institutional Review Boards of all investigative
institutions approved these studies, and all cases and controls gave
written informed consent.
Clinical data for the cases was obtained from medical records
which were reviewed and tabulated at each institution. We chose
to examine the ACR criteria [1] (http://www.rheumatology.org/
publications/classification/SLE/sle.asp) and age at diagnosis,
categorizing the age at diagnosis for association analyses. The
mean and median for age at diagnosis were 34 and 32,
respectively; we chose a cutoff for early diagnosis of under 30
years of age versus greater than or equal to 30 years of age. We
also chose to examine production of autoantibodies to double-
stranded DNA (anti-dsDNA), as this is typically associated with
severe disease and this was available in the clinical data from all
sites. Finally, we used more detailed nephritis information
available for the UCSF and ABCoN cohorts, namely a
characterization of those patients with severe nephritis as defined
by end-stage renal disease or histopathologic evidence of severe,
progressive renal disease on renal biopsy.
Genotyping and SNP Selection
Genotype data were obtained from two parent studies (see
Table 1). The four SLE case series and 1762 NYHP controls were
genotyped using the Illumina HumanHap550 array as part of a
genome-wide association study of SLE [10]. In addition, three of
the case series (UCSF, ABCoN, and MADGC) and 1243 NYHP
controls were genotyped for 67 SNPS in the STAT1/STAT4
region of chromosome 2q as part of a case-control study of STAT4
and two systemic autoimmune diseases, rheumatoid arthritis and
SLE [3]. Selection and genotyping of these 67 fine-mapping SNPs
was done by the National Institute for Arthritis and Musculoskel-
etal and Skin Diseases (NIAMS), using Sequenom MassARRAY
Technology as previously described [3]. From the Illumina 550K
panel, 91 contiguous SNPs from the STAT1/STAT4 region,
extended with flanking regions 200kb on either side, were selected;
of these, 45 were contained in the same region as the 67 SNPs,
with 21 of those being identical. Coverage of these SNPs was
analyzed using Tagger [11] in Haploview [12] with an r
2 threshold
Author Summary
Systemic lupus erythematosus is a chronic disabling
autoimmune disease, most commonly striking women in
their thirties or forties. It can cause a wide variety of clinical
manifestations, including kidney disease, arthritis, and skin
disorders. Prognosis varies greatly depending on these
clinical features, with kidney disease and related charac-
teristics leading to greater morbidity and mortality. It is
also complex genetically; while lupus runs in families,
genes increase one’s risk for lupus but do not fully
determine the outcome. It is thought that the interactions
of multiple genes and/or interactions between genes and
environmental factors may cause lupus, but the causes
and disease pathways of this very heterogeneous disease
are not well understood. By examining relationships
between subtypes of lupus and specific genes, we hope
to better understand how lupus is triggered and by what
biological pathways it progresses. We show in this work
that the STAT4 gene, very recently identified as a lupus risk
gene, predisposes specifically to severe manifestations of
lupus, including kidney disease.
Table 1. Summary of available genotype and phenotype data* by cohort and genotyping platform.
Illumina 550K
genotyped
Sequenom
genotyped
Genotyped on both
platforms
Genotyped on either
platform
Phenotype data
available
UCSF** cases 611 583 580 614 614
ABCoN** cases 330 347 330 347 345
MADGC** cases 116 105 103 118 118
U. Pittsburgh cases 319 0 0 319 319
Total cases 1376 1035 1013 1398 1396
NYHP** controls 1762 1243 445 2560 N/A
*After removal of duplicate samples and first-degree relatives, but prior to other quality control filters.
**UCSF=University of California, San Francisco; ABCoN=Autoimmune Biomarkers Collaborative Network; MADGC=Multiple Autoimmune Disease Genetics Consortium;
NYHP=New York Health Project.
doi:10.1371/journal.pgen.1000084.t001
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from CEU (CEPH residents of Utah with ancestry from northern
and western Europe) with minor allele frequency .0.05.
Duplicate genotyping enabled an analysis of SNP concordance
between the two genotyping methods, and inclusion of genotypes
that were called by either method. Conflicting genotype calls were
dropped from analyses when using combined data.
Statistical Analysis
Subjects were first removed for whom there was evidence of
duplication or relatedness in the Illumina 550K data, using IBS
estimation in PLINK [13] (http://pngu.mgh.harvard.edu/
purcell/plink). For the choice of which sample to remove,
preference was first based on availability of phenotype data, and
then on overall genotyping call rate. SNPs were removed from
analysis that had a minor allele frequency less than 5%, greater
than 10% missing genotypes, or Hardy-Weinberg equilibrium
p,0.001 in controls.
In order to choose loci to examine for phenotype analyses, we
performed allelic and conditional tests. These analyses were
performed separately for the 91 SNPs from the Illumina 550K
panel and the 67 Sequenom SNPs, since they contained
overlapping but different sets of SNPs (Table S1) and subjects
(Table 1), and large amounts of missing data could bias haplotype
estimation. We also analyzed the full set of 137 SNPs together
using only the subset of subjects who were genotyped on both
platforms. For each analysis, subjects were removed that had less
than 90% genotyping. We first conducted allelic tests of cases and
controls using PLINK [13] and selected those that had p,0.005;
at this first screening stage we used a liberal p-value, considering
that there are well over 10 independent haplotype blocks in the
complete region. To eliminate redundant SNPs having effects only
due to linkage disequilibrium, we then performed conditional
analysis using WHAP [14] (http://pngu.mgh.harvard.edu/
purcell/whap).
SNP rs7574865 was chosen for phenotype analysis based on the
allelic and conditional analyses (see Results). SNP rs7574865 was
genotyped on both platforms with a very high rate of concordance
(see Results), so genotypes from both platforms were combined for
the phenotype analysis of rs7574865; the single subject for whom
the calls conflicted was dropped. We first performed case-only
analyses (e.g. presence of renal disorder versus no renal disorder)
to establish which subphenotypes are associated with rs7574865
variation. We then performed case-control analyses (e.g. SLE with
renal disorder versus controls) to examine the risk that is conferred
by rs7574865 on subtypes of SLE characterized by each of those
subphenotypes. In both sets of analyses, first bivariate odds ratios
(ORs) and 95% confidence limits were determined for each
subphenotype. To correct for variability among strata when
combining data from different cohorts, we used Mantel-Haenszel
tests and combined ORs. In order to investigate the possibility of
associations with unknown but common underlying disease
mechanisms, principal components analysis (PCA) was performed
using all subphenotypes except severe nephritis (a subclass of
nephritis, and available only for the UCSF and ABCoN case
series). Values for the first two principal components (PCs) were
evaluated as above as additional subphenotypes, categorized by
positive or negative.
To address the concern that case-control studies may give
spurious associations due to undetected population admixture or
population substructure differences between cases and the
controls, we utilized ancestry data for the Illumina 550K
genotyped subjects. Ancestry was derived from ancestry-informa-
tive markers (AIMs) contained in the Illumina 550K panel. First a
set of 235 AIMs was used to estimate percent European ancestry,
using STRUCTURE [15]. For those subjects with .90%
European ancestry, another set of 1409 EUROSTRUCTURE
[16] AIMs was used to estimate percent Northern European
versus Southern ancestry. Finally, a subset of 1253 subjects (751
cases and 502 controls) was identified that was homogeneous
based on the first four PCs determined by PCA using the 550K
panel and EIGENSTRAT[17] software. Minimum covariance
determinant (MCD) estimators of PC location and scatter were
calculated using R [18]; outliers were then determined using
robust Mahalanobis distance. The procedure was applied in two
steps, first using both cases and controls (significance level
a=0.05), and then using the case-only robust estimators of
location and scatter (a=0.10), which led to a more homogeneous
case-control sample set. The lgc was decreased from 1.256 to
1.045 for the homogeneous set when assessed using the 550K
panel (see Figure S1).
We analyzed the associations between $90% European versus
,90% European and $90% Northern European versus ,90%
Northern European ancestry and rs7574865 in controls, using an
allele-based exact test. We also reanalyzed all tests using the
homogeneous subset of subjects. Finally, in multivariate analysis
we adjusted for ancestry, sex, and disease duration. For this
multivariate analysis, ancestry was a 3-category variable as follows:
1) ,90% European, 2) $90% European and $90% Northern
European, and 3) $90% European and ,90% Northern
European. We chose this coding due to the highly skewed
distribution of continuous ancestry, and the collinearity between
the European and Northern European variables.
Since we are examining associations for 13 phenotypes, the issue
of multiple testing must be considered. However, since these are
not independent phenotypes, a simple Bonferroni correction of
a=0.05/13=0.004 is clearly overly conservative, while an
unadjusted a=0.05 is clearly liberal. For this reason we have
chosen to present unadjusted p-values so that these may be directly
interpreted by the reader.
Stata 9.2 (http://www.stata.com/) was used for correlations,
odds ratios and p-values, Mantel-Haenszel tests and combined
ORs, phenotype principal components analysis, and multivariate
logistic regressions.
Results
Subjects and Phenotypes
The numbers of independent cases and controls in each cohort
and a summary of available genotype and phenotype data are
listed in Table 1. For overlapping SNPs, including rs7574865,
there were 1396 genotyped cases with phenotype data, and 2560
genotyped healthy controls. A summary of subphenotypes by
cohort is presented in Table 2. There were significant differences
among the cohorts for all phenotypes except neurologic disorder
and age at diagnosis less than 30 years old.
Some of these phenotypes are highly correlated; in particular
anti-dsDNA is a subcriterion for the ACR immunologic criterion,
and is associated with renal disease. Pairwise correlation
coefficients, for those pairs having r.0.1, are shown in Table 3.
All p-values for these pairs were #0.0001. In principal
components (PC) analysis of the phenotype data, the top 3
components of the first PC are anti-dsDNA, the immunologic
criterion, and renal disease. The top 3 components of the second
PC are malar rash, photosensitivity, and discoid rash. Variables
corresponding to the first and second PCs were included in
phenotype analyses (see Methods).
Specificity of STAT4 for Severe SLE Manifestations
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Of the 67 Sequenom SNPs (shown with the study genotypes in
Figure 1A), 62 passed quality control filters, including MAF
$5%. These 62 SNPs had 86% coverage of the common
variation (MAF $5%) in the STAT1/STAT4 region. In the
Illumina 550K panel (shown with the study genotypes in
Figure 1B), 77 out of 91 SNPs passed quality control and had
83% coverage of the extended region obtained by adding flanking
markers 200kb on either side of the Sequenom STAT1-STAT4
region. A complete list of SNPs on both platforms passing our
quality control criteria, along with their MAF and percentage
genotyped, is provided in Table S1.
We examined the concordance between calls for the 21
overlapping SNPs and 1458 subjects who were genotyped using
both methods. Results for this are shown in Supplementary Table
S2. The average and minimum agreement were 99.90% and
99.65%, respectively. In particular for SNP rs7574865, the
agreement was 99.93%. Given this high rate of concordance, we
chose to merge genotype data for rs7574865 for the phenotype
analyses (see below).
Table 2. SLE phenotype status by cohort.
Phenotypes* UCSF** ABCON** MADGC** U. PITTSBURGH p-value***
Anti-nuclear autoantibodies 572/598 (95.7%) 328/343 (95.6%) 109/118 (92.4%) 314/319 (98.4%) 0.018
Arthritis 460/614 (74.9%) 251/345 (72.8%) 101/118 (85.6%) 289/319 (90.6%) 2.9E-10
Immunologic disorder 359/614 (58.5%) 272/345 (78.8%) 83/118 (70.3%) 236/319 (74.0%) 7.3E-11
Photosensitivity 484/614 (78.8%) 224/345 (64.9%) 94/118 (79.7%) 187/317 (59.0%) 5.5E-11
Hematologic disorder 387/614 (63.0%) 238/345 (69.0%) 65/118 (55.1%) 164/317 (51.7%) 3.2E-05
Anti-dsDNA autoantibodies
{ 284/587 (48.4%) 184/344 (53.5%) 59/118 (50.0%) 136/319 (42.6%) 0.047
Malar rash 282/614 (45.9%) 197/345 (57.1%) 67/118 (56.8%) 133/283 (47.0%) 0.0026
Oral ulcers 189/614 (30.8%) 207/345 (60.0%) 47/118 (39.8%) 173/318 (54.4%) 1.6E-20
Serositis 185/614 (30.1%) 168/344 (48.8%) 49/118 (41.5%) 140/316 (44.3%) 2.0E-08
Diagnosis,30 years 233/605 (38.5%) 137/344 (39.8%) 36/90 (40.0%) 129/319 (40.4%) 0.94
Renal disorder 143/614 (23.3%) 116/345 (33.6%) 37/118 (31.4%) 96/318 (30.2%) 0.0033
Severe nephritis
{ 71/614 (11.6%) 38/345 (11.0%) NA NA 9.6E-05
Discoid rash 39/614 (6.4%) 56/345 (16.2%) 18/118 (15.3%) 15/283 (5.3%) 1.6E-07
Neurologic disorder 60/614 (9.8%) 30/345 (8.7%) 10/118 (8.5%) 29/317 (9.2%) 0.95
*See http://www.rheumatology.org/publications/classification/SLE/sle.asp for phenotype definitions.
**See Table 1 cohort definitions.
***Global exact test for association between phenotype status and cohort membership.
{Historical presence of positive anti-dsDNA test.
{Presence of end-stage renal disease or histopathologic evidence of severe, progressive renal disease on renal biopsy.
doi:10.1371/journal.pgen.1000084.t002
Table 3. Correlation coefficient rho for phenotype pairs with rho.0.1 and first two principal components.
Phenotypes* 1st PC** 2nd PC**
Renal
disorder
Immunologic
disorder
Anti-dsDNA
autoantibodies
Hematologic
disorder Serositis
Malar
Rash
Photo-
sensitivity
Renal disorder 0.59 0.21
Immunologic disorder 0.76 20.24 0.22
Anti-dsDNA autoantibodies 0.80 20.19 0.28 0.65
Hematologic disorder 0.36 - 0.15 0.10 0.14
Serositis 0.20 0.34 - - - -
Malar rash 0.14 0.66 0.10 - - - -
Photosensitivity 20.22 0.48 - 20.15 20.11 - - 0.19
Oral ulcers 20.10 0.34 - - - - 0.11 0.11 -
Age at diagnosis 20.50 20.39 20.28 20.17 20.20 20.13 20.11 20.19 -
Discoid rash - 0.42 - - - - - - 0.12
Anti-nuclear autoantibodies 0.17 20.12 - - 0.13 - - - -
Neurologic disorder 0.20 0.21 - - - - - - -
Significance is p,0.0001 for all pairs shown. Blank cells are given in the lower triangular matrix.
*See http://www.rheumatology.org/publications/classification/SLE/sle.asp for phenotype definitions.
**PC=principal component.
doi:10.1371/journal.pgen.1000084.t003
Specificity of STAT4 for Severe SLE Manifestations
PLoS Genetics | www.plosgenetics.org 4 May 2008 | Volume 4 | Issue 5 | e1000084Allele Tests and Conditional Analysis
Table 4 contains allelic p-values before and after conditioning
on the most significant SNP, for those with initial allelic p-values of
0.005 or less. We did four separate conditional analyses: (A)
subjects and SNPs genotyped on the Illumina 550K; (B) the
genetically homogeneous subset of subjects (see Methods) typed on
the Illumina 550K; (C) subjects and SNPs genotyped on the
Sequenom platform; and (D) all SNPs for those subjects that were
genotyped on both platforms. In the Illumina 550K panel,
rs7574865 (circled in Figure 1B) was the most significant SNP in
both the full set of subjects and the homogeneous subset (see
Methods). In the Sequenom 67-SNP set and in the combined set,
the 4 top SNPs were in high LD (D’=0.97 to 0.99, r
2=0.94 to
0.99) and made up a 4-marker haplotype for which the
components could not be independently analyzed (circled in
Figure 1A). Of the estimated individual haplotypes of these 4
markers, over 99% were either CGTC or TTCG, so that any one
SNP fully determined the other 3 in the vast majority of subjects.
The conditional p-values of Table 4 test the significance of each
SNP conditional on the values of the top SNP(s) which are given in
bold. While there were some results of borderline significance, they
were neither strong nor consistent across the different analyses.
The only compelling evidence after conditioning was for the 4-
locus haplotype above. Since any of the 4 SNPs serves as a marker
of this haplotype and rs7574865 is contained in both genotyping
sets, we chose to carry out phenotype analysis using this marker for
maximum power.
Ancestry Variability of rs7574865
We examined the minor allele frequencies for rs7574865 (Table
S3) in controls, for subsets as determined by STRUCTURE
analyses (see Methods). There were 130 controls with ,90%
European ancestry, for whom the minor allele frequency was
26.9%, versus 22.4% in the complementary 1601 controls with
$90% European ancestry (p=0.11). (The minor allele frequencies
of the HapMap populations are 33%, 28%, 16%, and 21%, for the
Figure 1. Haploview linkage disequilibrium map of D’ for 67 Sequenom STAT1/STAT4 SNPs in 2278 study subjects. (A) Green markers
are in STAT1 and STAT4 genes as indicated. Four SNPs comprising the top SLE risk haplotype, from allelic and conditional analyses (Table 4 (C)), are
circled. (B) Haploview linkage disequilibrium map of D’ for 91 Illumina 550K STAT1/STAT4 extended region SNPs in 3138 study subjects. Green
markers are in STAT1 and STAT4 genes as indicated. The top SLE risk SNP rs7574865 from allelic and conditional analyses (Table 4 (A)) is circled.
doi:10.1371/journal.pgen.1000084.g001
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allele frequencies were very similar, 22.1% and 22.6% respective-
ly, for subjects of either ,90% or $90% Northern European
ancestry; thus we did not observe a Northern-Southern European
gradient for rs7574865. Analyses were repeated with the
homogeneous subset of cases and controls (n=1253) as described
in Methods.
Phenotype Case-Only Analysis
We first examined each subphenotype for association with
rs7574865 within the SLE cases. In unadjusted results (Table S4),
only one phenotype showed borderline evidence for heterogeneity
of association among the four SLE case series (p=0.04 for
immunologic disorder); thus we retained combined Mantel-
Haenszel odds ratios and p-values. The most significant associa-
tions were with anti-dsDNA autoantibodies and the first principal
component, OR=1.44 (95% CI 1.23–1.70), p=10
25, and
OR=1.43 (95% CI 1.21–1.70), p=3610
25, respectively. Severe
nephritis, available on a smaller subset of cases, had the highest
OR=1.50 (95% CI 1.11–2.01), p=0.0075. There was also
support for associations with immunologic criteria (OR=1.24,
p=0.017), renal disorder (OR=1.23, p=0.024), age at diagnosis
under 30 (OR=1.22, p=0.018), and an inverse association with
oral ulcers (OR=0.80, p=0.0087).
Table 5 contains case-only analyses, for phenotypes having
unadjusted p,0.05, repeated first on the homogeneous subset of
Table 4. Allelic and conditional tests for all SNPs with p,0.005.
SNP
Single-marker
Allelic P-value
Single-marker
Allelic OR
P Conditioned on
top SNP(s) in bold
A) Illumina 550K n=3132 rs3821236 3.1E-08 1.40 0.73
rs16833215 0.00042 1.21 0.45
rs1517352 0.00028 1.21 0.025
rs10168266 1.4E-08 1.41 0.81
rs7601754 0.00015 0.77 0.062
rs10931481 1.9E-07 1.32 0.050
rs7574865 8.2E-14 1.54 NA
rs6752770 0.0029 1.18 0.60
rs2356350 0.0052 1.16 0.55
B) Illumina 550K, Homogeneous subset n=1252 rs3821236 0.0011 1.40 0.71
rs10168266 0.0034 1.34 0.38
rs7601754 0.0016 0.71 0.039
rs10931481 0.0021 1.31 0.058
rs7574865 2.9E-06 1.57 NA
C) Sequenom STAT4 fine map n=2083 rs1547550 0.0032 1.21 0.10
rs16833177 0.0032 1.25 0.88
rs7601754 0.00054 0.75 0.075
rs11889341 1.3E-08 1.49 NA
rs12998748 0.0021 0.71 0.084
rs6434435 0.0034 0.78 0.22
rs10931481 9.2E-06 1.34 0.56
rs13011805 0.0024 0.72 0.092
rs7574865 1.1E-08 1.50 NA
rs8179673 2.2E-08 1.48 NA
rs10181656 1.1E-08 1.50 NA
rs16833260 4.7E-05 1.30 0.29
rs6752770 0.0015 1.24 0.37
D) Illumina 550K and Sequenom combined
for subjects having both typing n=1351
rs10168266 0.0032 1.36 0.50
rs11889341 0.00019 1.44 NA
rs10931481 0.0010 1.34 0.75
rs7574865 0.00021 1.44 NA
rs8179673 6.9E-05 1.47 NA
rs10181656 5.1E-05 1.48 NA
rs16833260 0.0033 1.30 0.51
Allelic odds ratios (ORs) and p-values from PLINK, p-values conditional on bold SNPs from Whap [14]. Subjects with ,90% genotyping are excluded for each analysis. For
(C) and (D), the four top SNPs in bold are indistinguishable, i.e. any one fully determines the others in .99% of haplotypes.
doi:10.1371/journal.pgen.1000084.t004
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ancestry, sex, and disease duration. There is consistency in odds
ratios throughout and these analyses continue to support the
aforementioned phenotypic associations with rs7574865. Some
associations are even stronger in the homogeneous subset analysis,
for example severe nephritis (OR=1.79 [95% CI=1.20–2.67],
p=0.0039), renal disease (OR=1.48 [95% CI=1.16–1.88],
p=0.0016), and oral ulcers (OR=0.62 [95% CI=0.49–0.79],
p=0.0001).
Subphenotype-Control Analysis
Table 6 shows our primary results, the risk of SLE characterized
by each subphenotype versus healthy controls. This illustrates a
spectrum of minor allele frequencies for certain subphenotypes of
SLE, with the most extreme being severe nephritis, MAF=38.1%
(OR=2.12 [95% CI=1.58–2.83], p=4610
27), anti-dsDNA auto-
antibodies, MAF=35.1% (OR=1.86 [95% CI=1.63–2.13],
p=6 610
220), and the first principal component, MAF=35.0%
(OR=1.85 [95% CI=1.62–2.12], p=10
219). In contrast, controls
had a MAF of only 22.5% and cases as a whole had a MAF of
31.1%. SNP rs7574865 is also associated with higher risk for SLE
with renal disorder (OR=1.80, MAF=34.3%), diagnosis under 30
years old (OR=1.77, MAF=33.8%), and immunologic disorder
(OR=1.67, MAF=32.6%). There is also strong evidence that the
STAT4 risk allele is less frequent in SLE with oral ulcers,
MAF=28.8%, which is generally associated with milder disease.
Table 5. rs7574865 association with phenotype status of cases in homogeneous subset (n=751) and multivariate analyses.
Phenotypes
1 Homogeneous OR*
Homogeneous
p-value* Multivariate OR** Multivariate p-value**
Severe nephritis
{ 1.79 (1.20–2.67) 0.0039 1.43 (1.05–1.94) 0.022
Renal disorder 1.48 (1.16–1.88) 0.0016 1.18 (0.98–1.42) 0.074
First PC
{.0 1.42 (1.12–1.79) 0.0033 1.37 (1.15–1.63) 0.00047
Anti-dsDNA autoantibodies 1.40 (1.12–1.76) 0.0037 1.41 (1.19–1.67) 7.20E-05
Diagnosis ,30 years 1.35 (1.07–1.70) 0.012 1.22 (1.03–1.44) 0.020
Immunologic disorder 1.19 (0.94–1.52) 0.15 1.20 (1.00–1.44) 0.046
Oral ulcers 0.62 (0.49–0.79) 0.00010 0.81 (0.68–0.95) 0.012
1See Table 1 for phenotype definitions.
*Mantel-Haenzel odds ratio (OR) and p-value combined across cohorts.
**Multivariate logistic regression adjusting for sex; ancestry as a categorical variable (90% or greater Northern European, 90% or greater European but ,90% Northern
European, not 90% or greater European); and disease duration for all outcomes except age of diagnosis.
{UCSF and ABCoN only (see definitions Table 1): homogeneous n=461, multivariate n=790.
{First principal component of phenotypes (see Methods).
doi:10.1371/journal.pgen.1000084.t005
Table 6. rs7574865 MAFs and associations in subphenotype cases vs. controls.
All Subphenotype Cases and Controls Homogeneous Subset
Phenotypes
1 MAF OR (95% CI) p-value MAF OR (95% CI) p-value
Severe nephritis* 38.1% 2.12 (1.58–2.83) 4.1E-07 39.2% 2.35 (1.54–3.56) 5.1E-05
Anti-dsDNA autoantibodies 35.1% 1.86 (1.63–2.13) 6.3E-20 33.6% 1.85 (1.47–2.32) 7.0E-08
First PC**.0 35.0% 1.85 (1.62–2.12) 1.2E-19 34.0% 1.88 (1.49–2.37) 3.8E-08
Renal disorder 34.3% 1.80 (1.53–2.13) 3.4E-12 36.0% 2.05 (1.58–2.65) 2.8E-08
Diagnosis ,30 years 33.8% 1.77 (1.53–2.04) 2.6E-14 34.0% 1.89 (1.48–2.41) 1.8E-07
No oral ulcers 33.0% 1.70 (1.50–1.93) 3.3E-16 33.9% 1.87 (1.51–2.33) 4.4E-09
Immunologic disorder 32.6% 1.67 (1.48–1.90) 2.3E-17 31.3% 1.66 (1.35–2.06) 1.1E-06
All cases 31.1% 1.56 (1.40–1.73) 1.1E-16 30.0% 1.56 (1.29–1.90) 3.0E-06
No renal disorder 29.8% 1.47 (1.30–1.65) 2.10E-10 27.5% 1.39 (1.13–1.71) 0.0016
Diagnosis $30 years 29.5% 1.44 (1.27–1.64) 1.50E-08 27.7% 1.40 (1.13–1.74) 0.0019
Oral ulcers 28.8% 1.40 (1.21–1.61) 4.70E-06 25.0% 1.22 (0.96–1.55) 0.10
No immunologic disorder 27.9% 1.34 (1.14–1.58) 0.00047 27.5% 1.39 (1.08–1.79) 0.010
No anti-dsDNA autoantibodies 27.3% 1.30 (1.13–1.49) 0.00018 26.7% 1.33 (1.06–1.67) 0.013
Controls 22.5% -- 21.5% --
Results are 262 odds ratios with two-sided Fisher’s exact p-values.
1See Table 1 for phenotype definitions.
*Subset with nephritis detail (UCSF and ABCoN).
**First principal component of phenotypes.
doi:10.1371/journal.pgen.1000084.t006
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subset, again showing even stronger results for severe nephritis,
MAF=39.2% (OR=2.35 [95% CI 1.54–3.56]), and stronger
inverse results for oral ulcers, MAF=25.0%, versus MAF=30.0%
for all homogeneous cases and MAF=21.5% for homogeneous
controls.
Discussion
Genotype-phenotype associations between risk alleles and
disease subtypes may give insight into disease etiology and
mechanisms. Recent results show that rs7574865, a variant allele
of STAT4, confers an increased risk for both SLE and rheumatoid
arthritis (RA) [3,19], suggesting the involvement of common
pathways of pathogenesis among these two autoimmune diseases.
STAT4-deficiency is associated with accelerated renal disease and
increased mortality [20] in a murine lupus model, but with
protective effects for arthritis in knockout mice [21]. Since SLE is
an extremely heterogeneous disease, with multiple correlated
subphenotypes, we sought to investigate whether or not STAT4
appears to contribute to this phenotypic heterogeneity in human
SLE. We believe that our data provide compelling evidence that
STAT4 is associated with more severe SLE manifestations,
particularly with nephritis and with the production of autoanti-
bodies to double-stranded DNA. In contrast, other recently-
discovered SLE risk polymorphisms do not appear to be strongly
associated with severe disease manifestations [10].
There have been recent successes in the study of genotype-
phenotype associations in SLE and other autoimmune diseases.
For example, PDCD1 has been shown to be associated with lupus
nephritis and anti-phospholipid antibodies in ethnic subgroups [4],
and PTPN22 is primarily associated with anti-cyclic citrullinated
peptide (anti-CCP) [22] and rheumatoid factor (RF) [23]
autoantibody positive RA. The STAT4 gene has been shown to
be associated with both anti-CCP positive and negative RA [3]; it
has not yet been investigated in the context of SLE subphenotypes.
Replication of genotype-phenotype associations can be chal-
lenging [24]; a strength of our study is the inclusion of four
independent case series. Other strengths include the availability of
two overlapping genotype sets in the STAT4 region for most of the
subjects, including genome-wide data to facilitate ancestry
analysis, and of course the availability of detailed phenotype data
on all four of the case series.
A limitation of our study is that the subjects are of self-reported
European ancestry and primarily female. It could be insightful to
look at these associations in other populations, particularly since
SLE has higher prevalence among African-Americans and other
non-European populations [2]. The STAT4 gene has recently been
shown to be associated with RA in a Korean population [19];
however significant associations with subphenotypes – namely age
at onset, radiographic progression, and serologic status – were not
found.
Another limitation is the inherent difficulty in obtaining
accurate phenotype data. Differences between our 4 SLE cohorts
may be true differences in patient characteristics, perhaps as a
result of differences in selection, but could also be influenced by
different methods of assessment and accuracy of individual
records. However, although some of the phenotypes we examined
are related to disease activity, and may fluctuate naturally or as a
result of treatment, we classified SLE patients according to a
history of these specific phenotypes. We are encouraged by the fact
that our results were quite homogeneous across the different
cohorts. Also, any misclassification would presumably be non-
differential with respect to genotypes, thus diluting our results
rather than causing type I error.
Finally, it is important in genetic studies to protect against false
associations due to undetected population substructure. Indeed
there were some subjects in our cohort with sizeable non-
European ancestry, in spite of being self-reported European, and
those had a higher minor allele frequency for rs7574865.
However, reanalysis of a more homogeneous subset of subjects
of primarily northern European ancestry was very consistent with
our overall results. There is even stronger evidence in this subset
for relationships between the STAT4 rs7574865 SNP and nephritis
subphenotypes, and for an inverse relationship with oral ulcers.
Since the subphenotypes having the strongest risk conferred by
rs7574865 were highly correlated, we included clinical variables
based on principal components (PC) analysis to investigate the
possibility of common underlying effects. The first PC, associated
with the severe manifestations of anti-dsDNA antibodies, nephritis
and immunologic abnormalities, had similar associations as those
of its components. Severe nephritis was consistently the most
strongly associated subphenotype. The second PC, associated with
the milder skin disease manifestations of malar rash, photosensi-
tivity, and discoid rash, was not significantly associated with
rs7574865 in any analysis.
In summary, our study has identified multiple correlated
subphenotypes that are strongly associated with the STAT4 gene,
including nephritis, autoantibodies to double-stranded DNA, and
early age at diagnosis. The next challenge is identifying how these
correlated features fit into causal pathways, and therefore to help
elucidate the complex etiology of SLE.
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